Amgen, an American multinational biopharmaceutical company, has announced a $650 million expansion of its US manufacturing network, creating hundreds of new jobs.
The planned investment will support increased drug production at the company’s biologics manufacturing facility in Juncos and integrate innovative advanced technologies throughout the operations process. It is expected to create nearly 750 jobs, including construction roles and new highly skilled manufacturing jobs.
Robert A. Bradway, chairman and CEO at Amgen, says: “This expansion underscores Amgen’s commitment to US biomanufacturing and to strengthening the resilience of our global supply chain.
“By growing our capacity to deliver innovative medicines with cutting edge technology in our manufacturing plants, we will not only better serve patients but also create high-quality jobs that reinforce America’s leadership in biotechnology.”
Puerto Rico Governor Jenniffer González Colón says: Amgen’s multimillion-dollar expansion reflects a bond of mutual loyalty: Amgen’s sustained investment and Puerto Rico’s skilled, resilient workforce reinforcing each other over time.
“This new expansion not only strengthens US supply chain security through reshoring, it also opens new horizons for our people as we build an innovation ecosystem that positions Puerto Rico as the strongest biopharmaceutical hub in the United States.”
Sebastián Negrón Reichard, Puerto Rico Secretary of the Department of Economic Development and Commerce, says: “Puerto Rico boasts more than 60 years of expertise and excellence in the biopharmaceutical sector, supported by highly skilled talent and world-class infrastructure.
“This investment by Amgen is a testament to how committed we are to advancing a competitive and innovative ecosystem that allows global companies to grow and prosper in Puerto Rico.”
Amgen’s long-standing commitment to US innovation and state-of-the-art operations is reflected in more than $40 billion invested in manufacturing and research and development since the passage of the Tax Cuts and Jobs Act (TCJA) of 2017.
The enactment of pro-growth tax policies in TCJA, extended and reinforced by the One Big Beautiful Bill Act of 2025, further facilitates Amgen’s ability to invest domestically in cutting-edge science and manufacturing.
This announcement builds on Amgen’s other recent investments, including a $600 million science and innovation center in California and manufacturing expansions of $900 million in Ohio and $1 billion in North Carolina, respectively.
